卡培他滨联合多西他赛治疗复发乳腺癌的临床效果  

Clinical Effect of Capecitabine combined with Docetaxel in the Treatment of recurrent Breast Cancer

作　　者：刘威 LIU Wei(Department of Oncology,Minquan County People's Hospital in Shangqiu,Shangqiu Henan 476800,China)

机构地区：[1]河南商丘市民权县人民医院肿瘤科,河南商丘476800

出　　处：《临床研究》2022年第4期86-89,共4页Clinical Research

摘　　要：目的探讨复发乳腺癌患者采用卡培他滨联合多西他赛治疗的临床疗效。方法选取河南商丘市民权县人民医院2019年7月至2020年7月收治的90例复发乳腺癌患者作为研究对象,根据随机数字表法分为对照组(n=45)与观察组(n=45),对照组给予多西他赛治疗,观察组在对照组基础上联合卡培他滨治疗,比较两组临床疗效、治疗前后血清肿瘤标记物水平、不良反应发生率及治疗前后生存质量。结果观察组客观有效率(ORR)明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)、糖类抗原199(CA199)水平均较治疗前明显下降,且观察组水平明显低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,两组卡式功能状态评分标准Karnofsky(KPS)评分较治疗前明显提高,且观察组评分明显高于对照组,差异均有统计学意义(P<0.05)。结论多西他赛联合卡培他滨应用于复发乳腺癌治疗,能够提高临床疗效及生存质量,降低血清肿瘤标记物水平,且不会增加不良反应发生率。Objective To investigate the effect of capecitabine combined with docetaxel on the clinical effect of recurrent breast cancer patients.Methods A total of 90 patients with recurrent breast cancer who were admitted in Minquan County People's Hospital in Shangqiu,Henan Province from July 2019 to July 2020 were selected as the research objects,and they were divided into the control group(n=45)and the observation group(n=45)according to the random number table method.The control group was treated with docetaxel alone,and the observation group was treated with capecitabine on the basis of the control group.The clinical efficacy,serum tumor marker levels,incidence of adverse reactions and quality of life were compared between the two groups.Results Compared with the control group,the objective response rate(ORR)of the observation group was significantly higher(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),and carbohydrate antigen 199(CA199)in the two groups were significantly lower than those before treatment(P<0.05),compared with the control group,the level of the observation group was significantly lower(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Karnofsky functional status scale(KPS)scores in the two groups after treatment were significantly higher than those before treatment(P<0.05),and compared with the control group,the scores in the observation group were significantly higher(P<0.05).Conclusion Docetaxel combined with capecitabine in the treatment of recurrent breast cancer can improve the clinical efficacy and quality of life,reduce the level of serum tumor markers,and will not increase the incidence of adverse reactions.

关 键 词：卡培他滨 多西他赛 复发乳腺癌 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]